Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways
International Journal of Biological Sciences · 2026
DOI: 10.7150/ijbs.134269 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2026. Verfasst von Md Hafiz Uddin und 30 weiteren Autor:innen. Beteiligte Einrichtung: Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Transcriptome, Neuroendocrine Tumors. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Sporadic pancreatic neuroendocrine tumors (pNETs) with wild-type MEN1 represent a major yet largely ignored subset whose biology and metastatic potential remain poorly understood. Because metastasis can occur despite low histologic grade and modest mutational burden, we hypothesized that metastatic competence in MEN1-wild-type pNETs reflects quantitative reinforcement of shared oncogenic pathways rather than distinct mutational processes. We profiled 75 primary WHO G1/G2 pNETs by whole-exome and RNA sequencing, including 25% with lymph node and/or liver metastasis, and integrated genomic and transcriptomic data to connect pathway lesions with expression state. Metastatic tumors showed a slight increase in mutation frequency but conserved base-substitution spectra relative to non-metastatic cases, and adverse clinicopathologic features were enriched in Grade 2 disease. Aggregating alterations to pathways revealed broad convergence on canonical networks, with transcriptomic analyses demonstrating cohort-wide enrichment of Calcium, WNT, and KRAS/PI3K-AKT programs in metastasis. Intersection of significantly mutated genes with differentially expressed genes identified a focused 29-gene overlap, including RYR1 and ZNF273, that marks these convergent axes and distinguishes metastatic from non-metastatic tumors. Gene set enrichment confirmed preferential activation of Calcium, WNT, and PI3K-AKT signaling in metastatic tumors, consistent with a network-intensity model of progression. Finally, upstream-regulator analysis (iPathwayGuide) and gene-centric perturbation mapping (Gene2Drug) nominated candidate targeted and repurposable agents predicted to reverse the metastatic expression phenotype and flagged drugs unlikely to provide benefit, yielding a prioritized, testable therapeutic shortlist which includes fasudil and spaglumic acid. Convergent, domain-specific mutational patterns in highly mutated genes such as ZNF273 and CLCA1 define a molecular signature that could stratify metastatic risk in low-grade pNETs. Functional validation identified ZNF273 and RYR1 as candidate effectors of metastatic fitness in MEN1-wild-type pNETs, as siRNA-mediated silencing reduced cell viability, clonogenicity, spheroid growth, and migration in BON1 and QGP1 models. Predicted compounds showed in vitro activity, with doxorubicin exhibiting the strongest cytotoxic effect, supporting a therapeutically tractable KRAB-ZNF/calcium signaling axis in metastatic pNETs. Collectively, our data reframe metastasis in MEN1-wild-type low-grade pNETs as a property of pathway state rather than mutation quantity and provide a translational blueprint for biomarker-guided therapy development focused on Calcium, WNT, and KRAS/PI3K hubs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
- Emory Winship Cancer Institute, Atlanta, GA, USA.
- Lawrence Technological University, Southfield, MI, USA.
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC, USA.
- Trinity Health Oakland, Pontiac, MI, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Uddin, M. H., Mahdi, Z., Muqbil, I., Herring, B. R., Rose, B., Khan, H. Y., Li, Y., Aboukameel, A., Bannoura, S. F., Jimenez, H., Johansen, A. M., Al-Hallak, M. N., Azar, I., Mohamed, A., Hadid, T., Vaishampayan, N., Shi, Y., Wan, Y., Ong, V., …, & Azmi, A. S. (2026). Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.134269
Vancouver
Uddin MH, Mahdi Z, Muqbil I, Herring BR, Rose B, Khan HY, et al. Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways. International Journal of Biological Sciences. 2026. doi:10.7150/ijbs.134269
BibTeX
@article{Uddin2026,
author = {Uddin, Md Hafiz and Mahdi, Zaid and Muqbil, Irfana and Herring, Brendon R and Rose, Bart and Khan, Husain Y and Li, Yiwei and Aboukameel, Amro and Bannoura, Sahar F and Jimenez, Hugo and Johansen, Allan M and Al-Hallak, Mohammed Najeeb and Azar, Ibrahim and Mohamed, Amr and Hadid, Tarik and Vaishampayan, Nitin and Shi, Yang and Wan, Yin and Ong, Vy and Dyson, Gregory and Beydoun, Rafic and Tobon, Miguel and Beal, Eliza W and Chen, Herbert and Shields, Anthony F and Philip, Philip A and Beebe-Dimmer, Jennifer and Mohammad, Ramzi M and Pasche, Boris C and El-Rayes, Bassel F and Azmi, Asfar S},
title = {Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways},
journal = {International Journal of Biological Sciences},
year = {2026},
doi = {10.7150/ijbs.134269}
}
EUVIMED